[go: up one dir, main page]

AR049548A1 - DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS - Google Patents

DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS

Info

Publication number
AR049548A1
AR049548A1 ARP050102169A ARP050102169A AR049548A1 AR 049548 A1 AR049548 A1 AR 049548A1 AR P050102169 A ARP050102169 A AR P050102169A AR P050102169 A ARP050102169 A AR P050102169A AR 049548 A1 AR049548 A1 AR 049548A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
optionally substituted
independently selected
substituted
Prior art date
Application number
ARP050102169A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049548(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR049548A1 publication Critical patent/AR049548A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados de aminopiridina y su uso como fármacos, que son una clase de agonistas de dopamina, más particularmente una clase de agonistas que son selectivos para D3 sobre D2. Estos compuestos son utiles para el tratamiento y/o prevencion de la disfuncion sexual, por ejemplo la disfuncion sexual femenina (FSD), en particular el trastorno de la excitacion sexual femenina (FSAD), trastorno del deseo sexual hipoactivo (HSDD, falta de interés en el sexo), trastorno orgásmico femenino (FOD; incapacidad para alcanzar el orgasmo); y la disfuncion sexual masculina, en particular la disfuncion eréctil masculina (MED). La disfuncion sexual masculina segun se refiere en la presente memoria se supone que incluye trastornos eyaculatorios tales como eyaculacion precoz, anorgasmia (incapacidad para alcanzar el orgasmo) o trastornos del deseo tales como el trastorno del deseo sexual hipoactivo (HSDD; falta de interés en el sexo). Estos compuestos también son utiles para tratar trastornos neuropsiquiátricos y trastornos neurodegenerativos. Reivindicacion 1: Los compuestos de formula (1), en la que R1 se selecciona de H y alquilo C1-6; R2 se selecciona de H y alquilo C1-6; R3 se selecciona de formulas (2), (3) o (4) en las que A representa O; S o CH2; n es 1 o 2; R4 se selecciona de H y alquilo C1-6; en el que dicho alquilo C1-6 puede estar opcionalmente sustituido con 1 o 2 sustituyentes cada uno independientemente seleccionados de alquilo C1-6, OR7, fenilo, fenilo sustituido y heteroarilo; R5 se selecciona de H y alquilo C1-6; en el que dicho alquilo C1-6 puede estar opcionalmente sustituido con 1 o 2 grupos OR7; R6 se selecciona de H y alquilo C1-6; R7 se selecciona de H y alquilo C1-6; en el que dicho alquilo C1-6 puede estar opcionalmente sustituido con un fenilo, o un grupo fenilo sustituido; R8 se selecciona de H; metilo, etilo, metoxi, y etoxi; R9 representa alquilo C1-6; y R10 se selecciona de H y alquilo C1-6; en el que dicho alquilo C1-6 puede estar opcionalmente sustituido con 1 o 2 sustituyentes cada uno independientemente seleccionados de OR7, fenilo o fenilo sustituido; en el que heteroarilo significa un anillo aromático de 5 a 7 miembros, que contiene de 1 a 4 heteroátomos, dicho heteroátomo independientemente seleccionado de O, S y N; dicho heteroarilo puede estar opcionalmente sustituido con 1 o más sustituyentes cada uno independientemente seleccionado de alquilo C1-6, halo y OR7, cada sustituyente puede ser igual o diferente; y en el que fenilo sustituido significa fenilo sustituido con 1 o más sustituyentes cada uno independientemente seleccionado de alquilo C1-6, halo y OR7, cada sustituyente puede ser igual o diferente; a condicion de que: cuando R1 y R2 son H, R3 es el resto de formula (2), A es O, R5 es H o alquilo C1-6 y R6 es H o alquilo C1-6, entonces R4 no puede ser n-propilo; y sus sales, solvatos, polimorfos y profármacos farmacéuticamente aceptables.Aminopyridine derivatives and their use as drugs, which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and / or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD, lack of interest in sex), female orgasmic disorder (FOD; inability to reach orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is supposed to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to reach orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful for treating neuropsychiatric disorders and neurodegenerative disorders. Claim 1: The compounds of formula (1), wherein R 1 is selected from H and C 1-6 alkyl; R2 is selected from H and C1-6 alkyl; R3 is selected from formulas (2), (3) or (4) in which A represents O; S or CH2; n is 1 or 2; R4 is selected from H and C1-6 alkyl; wherein said C1-6 alkyl may be optionally substituted with 1 or 2 substituents each independently selected from C1-6 alkyl, OR7, phenyl, substituted phenyl and heteroaryl; R5 is selected from H and C1-6 alkyl; wherein said C1-6 alkyl may be optionally substituted with 1 or 2 OR7 groups; R6 is selected from H and C1-6 alkyl; R7 is selected from H and C1-6 alkyl; wherein said C1-6 alkyl may be optionally substituted with a phenyl, or a substituted phenyl group; R8 is selected from H; methyl, ethyl, methoxy, and ethoxy; R9 represents C1-6 alkyl; and R10 is selected from H and C1-6 alkyl; wherein said C1-6 alkyl may be optionally substituted with 1 or 2 substituents each independently selected from OR7, phenyl or substituted phenyl; wherein heteroaryl means a 5- to 7-membered aromatic ring, containing from 1 to 4 heteroatoms, said heteroatom independently selected from O, S and N; said heteroaryl may be optionally substituted with 1 or more substituents each independently selected from C1-6 alkyl, halo and OR7, each substituent may be the same or different; and wherein substituted phenyl means phenyl substituted with 1 or more substituents each independently selected from C1-6 alkyl, halo and OR7, each substituent may be the same or different; provided that: when R1 and R2 are H, R3 is the remainder of formula (2), A is O, R5 is H or C1-6 alkyl and R6 is H or C1-6 alkyl, then R4 cannot be n -propyl; and its pharmaceutically acceptable salts, solvates, polymorphs and prodrugs.

ARP050102169A 2004-05-27 2005-05-26 DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS AR049548A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
AR049548A1 true AR049548A1 (en) 2006-08-16

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102169A AR049548A1 (en) 2004-05-27 2005-05-26 DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS

Country Status (21)

Country Link
EP (1) EP1758862A1 (en)
JP (1) JP4198183B2 (en)
AP (1) AP2006003824A0 (en)
AR (1) AR049548A1 (en)
AU (1) AU2005247699A1 (en)
BR (1) BRPI0511571A (en)
CA (1) CA2567935C (en)
EA (1) EA200601982A1 (en)
EC (1) ECSP067029A (en)
GT (1) GT200500125A (en)
IL (1) IL179314A0 (en)
MA (1) MA28607B1 (en)
MX (1) MXPA06013786A (en)
NL (1) NL1029139C2 (en)
NO (1) NO20065326L (en)
PA (1) PA8635101A1 (en)
PE (1) PE20060366A1 (en)
SV (1) SV2005002129A (en)
TW (1) TW200609216A (en)
UY (1) UY28925A1 (en)
WO (1) WO2005115985A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) * 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
CA2752105C (en) * 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
EP2558437B1 (en) * 2010-04-12 2015-08-05 Supernus Pharmaceuticals, Inc. Methods for producing viloxazine salts and novel polymorphs thereof
US9504949B2 (en) 2011-06-30 2016-11-29 Donaldson Company, Inc. Air/oil separator assemblies; components; and methods
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
HRP20241015T1 (en) 2016-07-20 2024-11-08 Novartis Ag AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
IL274868B2 (en) * 2017-12-08 2024-06-01 Boehringer Ingelheim Int Imidazopyridine derivatives and the use thereof as medicament
US12479838B2 (en) * 2019-04-12 2025-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
MX2022006176A (en) 2019-11-22 2022-08-17 Incyte Corp COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR.
PH12022553501A1 (en) 2020-06-16 2024-04-22 Incyte Corp Alk2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
NZ540505A (en) * 2002-12-10 2007-02-23 Pfizer Morpholine derivatives for use as dopamine agonists in the treatment of I.A. sexual dysfunction

Also Published As

Publication number Publication date
UY28925A1 (en) 2005-12-30
AU2005247699A1 (en) 2005-12-08
GT200500125A (en) 2006-01-10
NO20065326L (en) 2006-12-19
PA8635101A1 (en) 2006-05-16
JP4198183B2 (en) 2008-12-17
WO2005115985A1 (en) 2005-12-08
BRPI0511571A (en) 2008-01-02
JP2008500331A (en) 2008-01-10
AP2006003824A0 (en) 2006-12-31
ECSP067029A (en) 2006-12-29
EP1758862A1 (en) 2007-03-07
IL179314A0 (en) 2007-03-08
CA2567935A1 (en) 2005-12-08
PE20060366A1 (en) 2006-05-15
TW200609216A (en) 2006-03-16
MA28607B1 (en) 2007-05-02
MXPA06013786A (en) 2007-01-25
CA2567935C (en) 2009-10-27
NL1029139C2 (en) 2006-06-19
SV2005002129A (en) 2005-12-13
EA200601982A1 (en) 2007-04-27
NL1029139A1 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
PE20181024A1 (en) DERIVATIVES OF CYCLOHEXANE SUBSTITUTED WITH AMIDO
PE20210163A1 (en) NEW PYRIDOPYRIMIDINONES REPLACED WITH BENZYLAMINE AND DERIVATIVES AS SOS INHIBITORS1
PE20220931A1 (en) PYRAZOLO[3,4-B]PYRAZINE-TYPE SHP2 PHOSPHATASE INHIBITORS
AR085960A1 (en) 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2
PE20181298A1 (en) BIVALENT BROMODOMINIUM INHIBITORS AND USES OF THEM
ES2669189T3 (en) Carbazole compounds useful as bromodomain inhibitors
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CO2017000438A2 (en) Heterocyclic carboxylic acids as soluble guanylate cyclase activators
PE20200665A1 (en) SPIROCYCLICAL COMPOUNDS AND THEIR METHODS OF PREPARATION AND USE
AR046200A1 (en) DERIVATIVES OF PIRAZINA AND ITS PHARMACEUTICAL USE. PHARMACEUTICAL PREPARATION AND COMPOSITION PROCESSES
AR079327A1 (en) DERIVATIVES OF 2-AMINO-5,5-DIFLUOR -5,6-DIHIDRO-4H- (1,3) OXAZIN-4-IL) PHENYL) -AMIDA
PE20191784A1 (en) VMAT2 INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS RELATING TO THEM
AR048289A1 (en) ETERES OF RING IMIDAZO SULFONA REPLACED.
ECSP16025201A (en) PIRIDONE AMIDES PROPHARMACES USEFUL AS SODIUM CHANNEL MODULATORS
UY35551A (en) HETEROARILE DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
PE20170268A1 (en) HETEROARYL COMPOUNDS FOR KINASE INHIBITION
PE20161443A1 (en) COMPOUNDS
PE20130149A1 (en) DERIVATIVES OF CHROMENONE WITH ANTI-TUMOR ACTIVITY
PE20191495A1 (en) PYRIDONAMIDES AS SODIUM CHANNEL MODULATORS
ECSP15012804A (en) ALCOXYPYRAZOLES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS
AR069510A1 (en) ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10
AR079164A1 (en) HETEROCICLIC DERIVATIVES OF INDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USE OF THE SAME FOR THE PROPHILAXIS OR TREATMENT OF ALLERGIC, INFLAMMATORY AND / OR AUTOIMMUNE DISEASES.
AR049548A1 (en) DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS
CO2019001181A2 (en) Heteroarylcarboxamide compounds as ripk2 inhibitors
AR078278A1 (en) ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure